Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback